Many FAK inhibitors have been tested in various cancer types with disappointing results.621 IN10018 is a FAK inhibitor that showed robust efficacy in patients with platinum-resistant recurrent ovarian cancer.622 IN10018 is under evaluation in a phase I trial in previously treated locally advanced or metastatic G/GEJ adenocarcinoma (NCT05327231). This evidence concerns the gene PTK2 and ovarian cancer.